Evidence map›Paper›PMID 30767128›Full record

ArticleClinical pharmacokinetics2019

Impact of Ethnicity-Specific Hepatic Microsomal Scaling Factor, Liver Weight, and Cytochrome P450 (CYP) 1A2 Content on Physiologically Based Prediction of CYP1A2-Mediated Pharmacokinetics in Young and Elderly Chinese Adults.

Guo-Fu Li, Qing-Shan Zheng, Yichao Yu, Wei Zhong, Hong-Hao Zhou, Furong Qiu, Guangji Wang, Guo Yu, Hartmut Derendorf

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical pharmacokinetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. How to Handle Delayed or Missed Doses: A Population Pharmacokinetic Perspective.European journal of drug metabolism and pharmacokinetics · 2020
    Review
  13. Is Cystatin C Good Enough as a Biomarker for Vancomycin Dosing: A Pharmacokinetic Perspective.European journal of drug metabolism and pharmacokinetics · 2020
    Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Guo-Fu LiClinical Medical College, Yangzhou University, #98 West Nantong Rd., Yangzhou, Jiangsu, China.ORCID http://orcid.org/0000-0002-4628-9941
Qing-Shan ZhengCenter for Drug Clinical Research, Shanghai University of Chinese Medicine, Shanghai, China.
Yichao YuDepartment of Pharmaceutics, College of Pharmacy, University of Florida, 1345 Center Drive, P3-27, Gainesville, FL, 32610-0494, USA.
Wei ZhongClinical Medical College, Yangzhou University, #98 West Nantong Rd., Yangzhou, Jiangsu, China.
Hong-Hao ZhouDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Furong QiuLaboratory of Clinical Pharmacokinetics, Shuguang Hospital, Shanghai University of Chinese Medicine, Shanghai, China.
Guangji WangKey Lab of Drug Metabolism and Pharmacokinetics, China, Pharmaceutical University, Nanjing, Jiangsu, China.
Guo YuClinical Medical College, Yangzhou University, #98 West Nantong Rd., Yangzhou, Jiangsu, China. guoyu@yzu.edu.cn.
Hartmut DerendorfDepartment of Pharmaceutics, College of Pharmacy, University of Florida, 1345 Center Drive, P3-27, Gainesville, FL, 32610-0494, USA. hartmut@cop.ufl.edu.
Shanghai University · CNCentral South University · CNAmerican Association of Colleges of Pharmacy · USChina Pharmaceutical University · CNUniversity of Florida · USYangzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe vast majority of physiological and biological data required for physiologically based predictions are primarily available in Caucasians rather than other ethnic populations, which leads to a lack of confidence in the application of physiologically based pharmacokinetic (PBPK) modeling for ethnicity-specific prediction of pharmacokinetics in the Chinese population.

objectivesIn this study we recalibrate the system parameters of Chinese-specific PBPK modeling and explore for the first time the relative importance of ethnicity-specific microsomal protein per gram of liver (MPPGL), liver weight, and cytochrome P450 (CYP) 1A2 abundance to the projection of drug disposition mediated by CYP1A2 in young and elderly Chinese adults.

methodsChinese MPPGL levels and associated variability were parameterized and incorporated for the first time into ethnicity-specific PBPK models for the Chinese adults. Parameterization of Chinese liver weights was also recalibrated on the basis of autopsy data from Chinese individuals (n = 4081) across the entire adult age range. Uncertainty surrounding the Chinese-specific CYP1A2 content has also been explored and clarified by conducting ethnicity-related PBPK simulations under different scenarios. Various ethnicity-related or 'what-if' scenarios for PBPK modeling were implemented to assess the predictive performance and explore the relative importance of ethnicity-specific MPPGL and liver weight to the projection of drug disposition mediated by CYP1A2 in terms of two typical CYP1A2 substrates, caffeine and theophylline, in young and elderly Chinese adults by comparing the predicted concentration-time data and associated pharmacokinetic parameter estimates with observations.

resultsCompared with 0.85, the liver scalar of 0.9 generally produced more accurate liver weight levels in virtual Chinese peers. Additionally, simulated MPPGL levels on the basis of Caucasian data were not able to reflect the age-independent pattern observed in Chinese adults, dissimilar to that on the basis of Chinese-specific adult MPPGL data. The modeling Scenarios A and B provided similar predictions for theophylline pharmacokinetics in young Chinese adults across different age groups, while Scenario B provided the most accurate prediction for theophylline pharmacokinetics in elderly Chinese adults. However, the use of a stratified value of CYP1A2 content derived from a Han Chinese cohort with a small sample size instead of the pooled value of all Chinese cohorts involved regardless of Chinese sub-ethnicity resulted in inadequate prediction of CYP1A2-mediated pharmacokinetics in terms of caffeine and theophylline in either young or elderly Chinese subjects. Additionally, the impact of ethnic-specific MPPGL on predictive accuracy of theophylline pharmacokinetics in elderly Chinese subjects is more evident than that of liver weight.

conclusionWe provided quantitative information pertaining to Chinese-specific levels of liver weight and MPPGL, and recalibrated these system parameters for PBPK modeling for young and elderly Chinese subjects. Uncertainty surrounding the Chinese-specific CYP1A2 content has also been clarified. PBPK modeling based on the recalibrated system parameters can accurately simulate CYP1A2-mediated pharmacokinetics in both young and elderly Chinese adults, particularly in elderly individuals.

Indexed as

Models, BiologicalAdultAgedAgingAsian PeopleCytochrome P-450 CYP1A2FemaleHealthy VolunteersHumansLiverMaleMicrosomes, LiverMiddle AgedOrgan SizeYoung AdultCYP1A2 protein, humanCytochrome P-450 CYP1A2

Identifiers

PMID30767128
OpenAlexW2911614839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.